Biotech company Starpharma
(ASX:SPL) has today announced that the VivaGel® condom has received final regulatory approval and is now able to be marketed in Japan.
Starpharma has worked closely with its commercial partner for Japan, Okamoto Industries throughout the regulatory process.
Okamoto has already commenced key launch preparations, including labelling and manufacturing activities, and plans to launch the VivaGel® condom in the first half of 2019.
Okamoto is Japan’s leading marketer of condoms with a majority share of the Japanese condom market, which is one of the world’s largest condom markets and estimated to be in the order of US$500 million per annum.
Shares in Starpharma
(ASX:SPL) trading 5.5 per cent lower at $1.12
